Berger U, Wilson P, Thethi S, McClelland R A, Greene G L, Coombes R C
Ludwig Institute for Cancer Research, St. George's Hospital Medical School, London, United Kingdom.
Cancer Res. 1989 Sep 15;49(18):5176-9.
Using a rat monoclonal antibody raised against human progesterone receptor (PR) we have developed an immunocytochemical technique to detect PR in human normal and malignant breast tissue and have compared the distribution of this with that obtained by the conventional dextran-coated charcoal steroid-binding assay. Immunoreactive PR was detected exclusively in the nuclei of epithelial cells in 29/51 (56.9%) of breast cancers studied. There was an excellent correlation between the immunocytochemical and dextran-coated charcoal techniques, with concordance in 43/51 (84.3%) cases [regression coefficient (Spearman) = 0.78; P less than 0.001]. The relationship between PR and estrogen receptor (ER) was also examined immunocytochemically using a monoclonal antiserum to ER. Twenty-eight out of 51 (54.9%) tumors were positive for both receptors and 13/51 (25.5%) negative for both. ER-positive, PR-negative tumors were found in 9/51 (17.6%) cases whereas only one case (2%) was PR-positive, ER-negative.
我们使用一种针对人孕激素受体(PR)产生的大鼠单克隆抗体,开发了一种免疫细胞化学技术,用于检测人正常和恶性乳腺组织中的PR,并将其分布情况与传统的葡聚糖包被活性炭类固醇结合测定法所得结果进行了比较。在所研究的51例乳腺癌中,有29例(56.9%)的免疫反应性PR仅在上皮细胞核中检测到。免疫细胞化学技术与葡聚糖包被活性炭技术之间存在极好的相关性,43/51(84.3%)的病例结果一致[回归系数(Spearman)=0.78;P<0.001]。还使用抗ER单克隆抗血清通过免疫细胞化学方法检测了PR与雌激素受体(ER)之间的关系。51例肿瘤中有28例(54.9%)两种受体均为阳性,13/51(25.5%)两种受体均为阴性。51例中有9例(17.6%)为ER阳性、PR阴性肿瘤,而只有1例(2%)为PR阳性、ER阴性。